MX2022003032A - Oxinitruro de piridina, metodo para su preparacion y uso de este. - Google Patents
Oxinitruro de piridina, metodo para su preparacion y uso de este.Info
- Publication number
- MX2022003032A MX2022003032A MX2022003032A MX2022003032A MX2022003032A MX 2022003032 A MX2022003032 A MX 2022003032A MX 2022003032 A MX2022003032 A MX 2022003032A MX 2022003032 A MX2022003032 A MX 2022003032A MX 2022003032 A MX2022003032 A MX 2022003032A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- method therefor
- sodium ion
- ion channel
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención pertenece al campo de la química médica. Se divulgan un oxinitruro de piridina, un método para su preparación y el uso de este. Específicamente, la presente invención se refiere a una serie de bloqueantes de los canales iónicos de sodio con una nueva estructura, un método para su preparación y el uso de estos. La estructura de estos es como se muestra en a continuación en la fórmula general (I). Los compuestos o un estereoisómero, un racemato, un isómero geométrico, un tautómero, un profármaco, un hidrato, un solvato o una sal farmacéuticamente aceptable de estos y una composición farmacéutica se puede utilizar para tratar o/y prevenir enfermedades relacionadas mediadas por un canal iónico de sodio (NaV). (ver Fórmula).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910863718 | 2019-09-12 | ||
CN201911094782 | 2019-11-11 | ||
CN202010531381 | 2020-06-11 | ||
CN202010923311 | 2020-09-04 | ||
PCT/CN2020/114700 WO2021047622A1 (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003032A true MX2022003032A (es) | 2022-07-12 |
Family
ID=74866555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003032A MX2022003032A (es) | 2019-09-12 | 2020-09-11 | Oxinitruro de piridina, metodo para su preparacion y uso de este. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230303495A9 (es) |
EP (1) | EP4043437A4 (es) |
JP (1) | JP2022548104A (es) |
KR (1) | KR20220101606A (es) |
CN (3) | CN118146148A (es) |
AU (1) | AU2020346951A1 (es) |
BR (1) | BR112022004495A8 (es) |
CA (1) | CA3150400A1 (es) |
CL (1) | CL2022000619A1 (es) |
CO (1) | CO2022004594A2 (es) |
MX (1) | MX2022003032A (es) |
PE (1) | PE20221515A1 (es) |
TW (1) | TWI770607B (es) |
WO (1) | WO2021047622A1 (es) |
ZA (1) | ZA202204100B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202300147A (zh) * | 2021-03-11 | 2023-01-01 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物晶型及其應用 |
AU2022285758A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
CN117813302A (zh) | 2021-06-04 | 2024-04-02 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂 |
CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
BR112023025264A2 (pt) | 2021-06-04 | 2024-02-20 | Vertex Pharma | Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida |
AU2022286438A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び(ハロ)アルコキシ置換テトラヒドロフラン |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
CN116891432A (zh) * | 2022-04-02 | 2023-10-17 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂及其用途 |
US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
TW202348229A (zh) * | 2022-06-02 | 2023-12-16 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物的製備方法 |
CN117263856A (zh) * | 2022-06-22 | 2023-12-22 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂 |
WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0752421B1 (en) * | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
AU2006260299B8 (en) * | 2005-06-21 | 2012-11-29 | Mitsui Chemicals, Inc. | Amide derivative and insecticide containing the same |
MX2008013194A (es) * | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
JP2010047480A (ja) * | 2006-12-19 | 2010-03-04 | Mitsui Chemicals Inc | 虫害の予防方法 |
CA2701766A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
AU2008310663A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
CA2822789A1 (en) * | 2010-12-22 | 2012-06-28 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
UY35288A (es) * | 2013-01-31 | 2014-08-29 | Vertex Pharma | Piridonamidas como moduladores de canales de sodio |
EP2951168B1 (en) * | 2013-01-31 | 2017-01-04 | Vertex Pharmaceuticals Incorporated | Quinoline and quinoxaline amides as modulators of sodium channels |
WO2014120820A1 (en) * | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
AP2016009287A0 (en) * | 2013-12-13 | 2016-06-30 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
TW201920081A (zh) * | 2017-07-11 | 2019-06-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑的羧醯胺 |
CA3105657A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
-
2020
- 2020-09-11 PE PE2022000407A patent/PE20221515A1/es unknown
- 2020-09-11 US US17/642,020 patent/US20230303495A9/en active Pending
- 2020-09-11 JP JP2022516434A patent/JP2022548104A/ja active Pending
- 2020-09-11 BR BR112022004495A patent/BR112022004495A8/pt unknown
- 2020-09-11 MX MX2022003032A patent/MX2022003032A/es unknown
- 2020-09-11 WO PCT/CN2020/114700 patent/WO2021047622A1/zh unknown
- 2020-09-11 TW TW109131318A patent/TWI770607B/zh active
- 2020-09-11 CN CN202410255352.5A patent/CN118146148A/zh active Pending
- 2020-09-11 KR KR1020227012157A patent/KR20220101606A/ko unknown
- 2020-09-11 CN CN202010957957.0A patent/CN112479996B/zh active Active
- 2020-09-11 CA CA3150400A patent/CA3150400A1/en active Pending
- 2020-09-11 CN CN202080037787.2A patent/CN113906013B/zh active Active
- 2020-09-11 EP EP20863934.4A patent/EP4043437A4/en active Pending
- 2020-09-11 AU AU2020346951A patent/AU2020346951A1/en active Pending
-
2022
- 2022-03-11 CL CL2022000619A patent/CL2022000619A1/es unknown
- 2022-04-11 CO CONC2022/0004594A patent/CO2022004594A2/es unknown
- 2022-04-11 ZA ZA2022/04100A patent/ZA202204100B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021047622A1 (zh) | 2021-03-18 |
BR112022004495A8 (pt) | 2023-04-18 |
CO2022004594A2 (es) | 2022-07-08 |
BR112022004495A2 (pt) | 2022-05-31 |
CN112479996B (zh) | 2023-05-26 |
CL2022000619A1 (es) | 2022-10-28 |
CN118146148A (zh) | 2024-06-07 |
PE20221515A1 (es) | 2022-10-04 |
US20230303495A9 (en) | 2023-09-28 |
CN113906013A (zh) | 2022-01-07 |
EP4043437A1 (en) | 2022-08-17 |
ZA202204100B (en) | 2024-04-24 |
CN113906013B (zh) | 2024-03-12 |
TW202114990A (zh) | 2021-04-16 |
KR20220101606A (ko) | 2022-07-19 |
TWI770607B (zh) | 2022-07-11 |
CA3150400A1 (en) | 2021-03-18 |
JP2022548104A (ja) | 2022-11-16 |
CN112479996A (zh) | 2021-03-12 |
AU2020346951A1 (en) | 2022-04-28 |
EP4043437A4 (en) | 2023-10-04 |
US20230026907A1 (en) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003032A (es) | Oxinitruro de piridina, metodo para su preparacion y uso de este. | |
MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
PH12017501570B1 (en) | Bicyclic ketone sulfonamide compounds | |
PH12019502436A1 (en) | 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors | |
MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
MY159615A (en) | Fused heterocyclic derivatives and methods of use as c-met inhibitors | |
MX2015007796A (es) | Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales. | |
MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
PH12021550958A1 (en) | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor | |
MX2019000451A (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
WO2020128614A8 (en) | Method for treating interstital lung disease | |
CR20200636A (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitorio para el tratamiento de una enfermedad parasitoria | |
TN2018000214A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. | |
PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
PH12020551117A1 (en) | Compositions for preventing or treating uveitis |